FIELD: immunology.
SUBSTANCE: use of a combination containing an antibody specific to CD19 and venetoclax in the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia or acute lymphoblastic leukemia that express CD19 is proposed. In addition, a method for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia or acute lymphoblastic leukemia that express CD19 is considered.
EFFECT: this invention can find further application in the therapy of cancer expressing CD19.
38 cl, 10 dwg, 8 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT APPROACH DESIGNED TO TREAT WITH A COMBINATION OF ANTI-CD19 ANTIBODY AND VENETOCLAX | 2018 |
|
RU2802812C2 |
| COMBINATION OF CD19 ANTIBODY AND BRUTON TYROSINE KINASE INHIBITOR AND THEIR APPLICATION | 2016 |
|
RU2756010C2 |
| COMBINATIONS AND USE THEREOF | 2016 |
|
RU2767063C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| FORMULATIONS BASED ON CD19 ANTIBODY | 2017 |
|
RU2748024C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| CELL | 2015 |
|
RU2768019C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR CANCER TREATMENT | 2017 |
|
RU2826270C2 |
| ANTI-TRBC1 ANTIGEN-BINDING DOMAIN | 2018 |
|
RU2791327C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
